Rankings
Publications
Search Publications
Cited-by Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Scilit
About Us
Advisory Board
Data Sources
Career
Support / Contact
User Guide
Publisher User
Search Function
Rankings Function
API Resource
Scilit Knowledge
Metrics
Scilit Recognitions
Publications Classification
Media
News
Blog
Login
Register
Home
Publications
Supplementary Table S3 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
Home
Publications
Supplementary Table S3 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
Supplementary Table S3 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
Authors:
YQ
Yunkai Qie
Yunkai Qie
SH
Shiwang Huang
Shiwang Huang
CS
Chong Shen
Chong Shen
ZW
Zhouliang Wu
Zhouliang Wu
LD
La Da
La Da
KJ
Kaipeng Jia
Kaipeng Jia
ZZ
Zhe Zhang
Zhe Zhang
GZ
Gangjian Zhao
Gangjian Zhao
LW
Lili Wang
Lili Wang
GX
Guoping Xu
Guoping Xu
YZ
Yang Zhao
Yang Zhao
RL
Rui Liang
Rui Liang
See more
Article Alert
Citation Alert
Add to Library
Cite
Download
Share
Download
Download PDF
Download
Open Access
Publisher website
Google Scholar
3 March 2025
other
Published by
American Association for Cancer Research (AACR)
DOI:
10.1158/1078-0432.28523304
Abstract
Supplementary Table S3. Immune-mediated adverse events.
Keywords
CLINICAL TRIAL RESULTS
PHASE II CLINICAL TRIALS
GENITOURINARY CANCERS
BLADDER CANCER
IMMUNOTHERAPY
CHECKPOINT BLOCKADE
Related articles
Scroll to top